Anti-beta-lactamase antibiotic composite preparation

Abstract

The invention discloses an anti-beta-lactamase antibiotic compound preparation comprising Ticarcillin and its salts, Sulbactam and its salts or Tazobactam and its salts, wherein the weight ratio of Ticarcillin and its salts, Sulbactam and its salts or Tazobactam and its salts is in the range of 1:1 to 10:1, the preferred weight ratio of Ticarcillin and its salts, Sulbactam and its salts is in the range of 2:1 to 6:1, preferably 2:1, the preferred weight ratio of Ticarcillin and its salts, Tazobactam and its salts is in the range of 1:1 to 6:1, preferably 4:1, The preparation has wider antimicrobial spectrum and stronger antibiotic action than Ticarcillin.

Description

technical field [0001] The invention relates to an anti-β-lactamase antibiotic compound preparation, in particular to a compound preparation composed of ticarcillin and its salt, sulbactam and its salt or tazobactam and its salt. Background technique [0002] Penicillin antibiotics have been widely used clinically and have played a positive role in human health. At the same time, due to the long-term and extensive clinical use, the problem of bacterial resistance to penicillin antibiotics is becoming more and more serious. The main mechanism of bacterial resistance to penicillin antibiotics is the production of specific β-lactamases (β-lactmases) to decompose drugs, including chromosome-mediated type I cephalosporinases and plasmid-mediated extended-spectrum β-lactamase. [0003] In order to overcome clinical drug-resistant infections caused by β-lactamase-producing bacteria, it is of great clinical significance to develop compound preparations of penicillin antibiotics an...

AI Technical Summary

Problems solved by technology

In recent years, with the increasing clinical use of ticarcillin, experimental studies have shown that some originally sensitive strains have developed resistance to ticarcillin, and the cure rate has declined.